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Background: Mantle cell lymphoma (MCL) is an aggressive and incurable form of non-Hodgkin’s lymphoma. Despite
initial intense chemotherapy, up to 50 % of cases of MCL relapse often in a chemoresistant form. We hypothesized that
the recently identified MCL-initiating cells (MCL-ICs) are the main reason for relapse and chemoresistance of MCL.
Cancer stem cell-related pathways such as Wnt could be responsible for their maintenance and survival.
Methods: We isolated MCL-ICs from primary MCL cells on the basis of a defined marker expression pattern
(CD34-CD3-CD45+CD19-) and investigated Wnt pathway expression. We also tested the potential of Wnt pathway
inhibitors in elimination of MCL-ICs.
Results: We showed that MCL-ICs are resistant to genotoxic agents vincristine, doxorubicin, and the newly approved
Burton tyrosine kinase (BTK) inhibitor ibrutinib. We confirmed the differential up-regulation of Wnt pathway in MCL-ICs.
Indeed, MCL-ICs were particularly sensitive to Wnt pathway inhibitors. Targeting β-catenin-TCF4 interaction with
CCT036477, iCRT14, or PKF118-310 preferentially eliminated the MCL-ICs.
Conclusions: Our results suggest that Wnt signaling is critical for the maintenance and survival of MCL-ICs, and effective
MCL therapy should aim to eliminate MCL-ICs through Wnt signaling inhibitors.
Keywords: Lymphoma-initiating cells, Tumor stem cells, Burton tyrosine kinase, Wnt3, FZD1, Mesenchymal stromal cells,
MCL co-culture, CCT036477, iCRT14, PKF118-310Background
Mantle cell lymphoma (MCL) is considered as an incur-
able subtype of non-Hodgkin’s lymphoma that causes sig-
nificant morbidity and early death presumably due to
relapsed disease [1–3]. Despite apparent clinical remis-
sions achieved with chemotherapy regimens (R-CHOP or
R-hyperCVAD), MCL relapse rates hover around 50 % [4,
5]. The relapse is considered to be due to chemoresistant
cells that prevent complete elimination of MCL cells.
A small fraction of cells within tumors have tumor-
initiating properties and are believed to be the source of re-
lapsed cancer. These cells are referred to as cancer stem
cells (CSCs) or tumor-initiating cells [6–9]. CSCs have been
implicated in the growth, progression, and relapse of several
tumor subtypes. The most current therapies target dividing
tumor cells while sparing non-dividing and inherently* Correspondence: fsamaniego@mdanderson.org
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creativecommons.org/publicdomain/zero/1.0/chemoresistant CSCs; thus, they fail to provide long-term
cures and result in tumor relapse [10, 11].
CSCs and normal hematopoietic stem cells share Wnt,
Notch, and Hedgehog signaling pathways, which are re-
quired for their growth and self-renewal [7]. Recent studies
have suggested a role of Wnt signaling in MCL tumorigen-
esis [12–14]. The Wnt signaling pathway regulates develop-
ment, and its dysregulation leads to oncogenesis [15–17].
Canonical Wnt signaling is initiated by the binding of Wnt
ligands to their cognate Frizzled (FZD) receptors and its co-
receptors, low density lipoprotein receptor related proteins
5/6 (LRP5/6). In the absence of Wnt signaling, β-catenin is
phosphorylated and its interaction with GSK-3β and axin-1
leads to its ubiquitination and degradation [18]. Activation
of the Wnt pathway prevents β-catenin phosphorylation-
induced degradation, and stabilized β-catenin accumulates
in the nucleus, where it forms active transcription com-
plexes with the T cell factor/lymphoid enhancer binding fac-
tor (TCF/LEF) family of DNA-binding transcription factorsrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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tumorigenesis [22, 23]. Selective targeting of stem cell signal-
ing pathways should eliminate CSCs [24].
MCL-initiating cells (MCL-ICs) have been recently iden-
tified based on a lack of CD19 marker (CD34-CD3-CD45
+CD19- cells) [25]. Two studies from different groups have
shown that these MCL-ICs can repopulate tumor in mice
[25, 26]. As few as 100 of CD19- MCL-ICs have been found
to produce whole tumor with both CD19+ and CD19- cells,
while CD19+ MCL-non-ICs were incapable of tumor de-
velopment at comparable limited dilutions in severe com-
bined immunodeficiency (SCID) mice [25, 26]. We suggest
that the high relapse rates of human MCL arise from in-
complete elimination of chemoresistant MCL-ICs [27].
Thus, in order to improve long-term survival of individuals
with MCL, it is important to have a fuller understanding of
the signaling pathways responsible for the chemoresistance
and maintenance of MCL-ICs. In this study, we investigated
the expression and importance of Wnt pathway in survival
of MCL-ICs and explored ways to eliminate these cells.
Results
MCL-ICs possess stem cell-like properties
Subpopulations of MCL-ICs (CD34-CD3-CD45+CD19-)
and MCL-non-ICs (CD34-CD3-CD45+CD19+) were iso-
lated from a MCL tumor sample based on a previously de-
scribed immunostaining and sorting protocol (Fig. 1a)
[25]. The purity and identity of the isolated MCL-ICs
population was confirmed by a lack of expression of sur-
face markers for plasma cells (CD27, CD38) and natural
killer cells (CD56, CD16) (Fig. 1b). Fluorescence in situ
hybridization analysis of isolated MCL-ICs and cyclin D1
expression confirmed the presence of t (11;14) (q13; q32)
(Fig. 1c). Presence of cyclin D1 overexpression in MCL-
ICs confirmed that MCL-ICs are clonal cells (Fig. 1d).
qRT-PCR analysis revealed enrichment of the stem cell
core transcription factors Nanog, Oct4, and KLF4 (5.29,
3.06, and >100-fold, respectively) in MCL-ICs compared
with MCL-non-ICs (Fig. 2a). However, Sox2 expression
was not significantly elevated in MCL-ICs (1.07-fold)
compared with B-cells (peripheral blood CD19+ cells).
qRT-PCR analysis also showed significantly higher (>100-
fold) expression of aldehyde dehydrogenase 1 (ALDH1)
and ALDH2 in MCL-ICs than in MCL-non-ICs (Fig. 2b);
this observation concurs with the high ALDH activity de-
tected in MCL-ICs (Fig. 2e). The expression levels of the
antioxidant enzymes MT1b and SOD2 were elevated over
sixfold in MCL-ICs, suggesting a higher reactive oxygen
species scavenging capacity (Fig. 2b). MCL-ICs also over-
expressed genes associated with chemoresistance, such as
those encoding the ATP transporters ABCC3 and ABCC6
as well as CD44 (>100-, 22-, and 3-fold, respectively) com-
pared with MCL-non-ICs (Fig. 2c). Cell cycle analysis
showed that 100 % of MCL-ICs were quiescent (in G0/G1phase), whereas MCL-non-ICs were distributed through-
out all phases of the cell cycle (G0/G1, 69.2 %; S, 9.16 %;
G2/M, 15.5 %) (Fig. 2d). Taken together, these results indi-
cate that MCL-ICs possess characteristic gene expression
of cancer stem cells.
Wnt pathway genes are overexpressed in MCL-ICs
Analysis from previous studies using unfractionated MCL
cells have implicated the Wnt pathway in the pathogenesis
of mantle cell lymphoma [12–14]. Therefore, we first in-
vestigated Wnt3 expression in unfractionated MCL. Our
observations suggest that 9 out of 20, nearly 45 % MCL
samples, overexpress Wnt3. We next investigated the ex-
pression of Wnt3 in MCL-ICs isolated from MCL samples
expressing high and low Wnt3 levels. Our results showed
that MCL-ICs were enriched in Wnt3 compared to MCL-
non-ICs and B-cells, irrespective of total tumor Wnt3 ex-
pression (Fig. 3a). We observed differential up-regulation
of Wnt ligands and their FZD receptors in MCL-ICs com-
pared with MCL-non-ICs (Fig. 3b, Table 1), using B-cells
as a reference. To show other evidence of enhanced Wnt
signaling, we performed immunostaining for β-catenin.
Higher cellular and nuclear levels of β-catenin were ob-
served in MCL-ICs than in MCL-non-ICs (Fig. 3c,
Additional file 1: Figure S1) whereas B-cells did not show
detectable β-catenin levels (Additional file 1: Figure S1).
Activation of Wnt signaling in MCL-ICs was confirmed
by the elevated expression of the Wnt target genes encod-
ing ID2 and TCF4 (both >100-fold) compared with MCL-
non-ICs (Fig. 3d). Thus, by 3 independent methods, we
show that the Wnt pathway is differentially up-regulated
in MCL-ICs.
Inhibition of Wnt signaling preferentially eliminates MCL-ICs
Treatment of primary MCL cells with chemotherapeutic
drugs (vincristine, doxorubicin, or ibrutinib) induced apop-
tosis in MCL cells but did not decrease the percentage of
MCL-ICs (1.79, 1.57, and 2.18 %, respectively) compared
with buffer control (1 % MCL-ICs) suggesting chemoresis-
tance of MCL-ICs to these agents (Fig. 4a). We analyzed the
effects of Wnt signaling inhibitors targeting the pathway ei-
ther upstream of β-catenin degradation (tankyrase inhibitor
XAV939, axin-1 stabilizer IWR1-endo, and porcupine in-
hibitor IWP2) or downstream at β-catenin-mediated tran-
scription complex (CCT036477, iCRT14, and PKF118-310)
(Fig. 5). MCL cells were treated with the known active
concentrations of these inhibitors and evaluated for the per-
centage of MCL-ICs. None of the agents acting upstream of
β-catenin degradation decreased the percentage of MCL-
ICs. On the other hand, chemical inhibitors of β-catenin-
TCF4 interaction, CCT036477, iCRT14, and PKF118-310,
effectively decreased the percentage of MCL-ICs from 1 %
in buffer control to 0.35, 0.68, and 0.44 %, respectively
(Fig. 4a) and induced apoptosis of MCL cells (Additional
Fig. 1 Isolation of MCL-ICs. (a) Isolation of MCL-ICs using immunostaining and flow sorting. (b) Immunostaining of isolated MCL-ICs for plasma
cell markers CD27/CD38 and natural killer cell markers CD56/CD16 detected by flow cytometry. (c) Detection of gene fusion t (11;14) (q13; q32) in
MCL-ICs using fluorescent in situ hybridization, indicated by arrow. (d) qRT-PCR expression of cyclin D1 in MCL-ICs, MCL-non-ICs relative to B-cells.
Differences between MCL-ICs and B-cells were significant (P < 0.05) for cyclin D1
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Fig. 2 Stem cell-like properties of MCL-ICs. a–c qRT-PCR performed using the total cellular RNA isolated from MCL-ICs (n = 4) for a stem cell
transcription factors (Nanog, Oct4, Sox2, Klf4), b ALDH isoforms and antioxidant enzymes SOD2 and MT1b, and c chemoresistance-associated
genes encoding ABCC3, ABCC6, and CD44. Differences between MCL-ICs and MCL-non-ICs were significant (P < 0.05) for ALDH1, ALDH2, SOD2,
MT1b, Nanog, Oct4, Klf4, ABCC3, ABCC6, and CD44. d Cell cycle analysis of isolated MCL-ICs, MCL-non-ICs, and total MCL cells by flow cytometry.
e ALDH activity in freshly isolated MCL-ICs from apheresis samples evaluated using ALDEFLUOR kit
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potent Wnt inhibitor, CCT036477, on the expression of
Wnt target genes and transcription factors associated with
stemness of MCL-ICs. Treatment with CCT036477 reduced
the expression of the Wnt target genes encoding PPARδ,
Cyclin D1, TCF4, and ID2 (1.64-, 1.96-, 2.56-, 8.33-, and
12.5-fold, respectively) (Fig. 4b), and the stem cell-specific
core transcription factors Nanog, Oct4, Sox2, Myc, and Klf4
(1.28-, 1.26-, 2-, 3.26-, and 3.67-fold, respectively) (Fig. 4c).
Gli2 was used as off-target negative control. In contrast,inhibitors of Hedgehog and Notch signaling pathways did
not decrease the percentage of MCL-ICs (Additional file 3:
Figure S3). Taken together, these results suggest that target-
ing β-catenin-TCF4 interaction can preferentially eliminate
MCL-ICs by effectively blocking Wnt signaling in MCL-ICs.
Discussion
The high rate of MCL relapse after initial apparent clinical
remissions achieved with conventional chemotherapy sug-
gests incomplete elimination of MCL cells and implicates
Fig. 3 Enrichment of Wnt signaling pathway genes in MCL-ICs. a Expression of Wnt3 in unfractionated MCLs (n = 20) and MCL-ICs isolated from
unfractionated MCLs expressing high (n = 3) and low (n = 3) Wnt3. b Expression of mRNAs encoding Wnt ligands and FZD receptors in freshly
isolated MCL-ICs and MCL-non-ICs relative to B-cells from healthy donors. Horizontal lines represent median for each group. Differences
between MCL-ICs and MCL-non-ICs were significant (P < 0.05) for Wnt3, Wnt7b, FZD1, FZD5, FZD9, and FZD6. c Immunostaining detection of
the expression and localization of β-catenin in freshly isolated MCL-ICs and MCL-non-ICs. Color image is included in Additional file 1: Figure S1.
d Relative expression levels of Wnt target genes encoding ID2 and β-catenin–interacting transcriptional factor TCF4 in MCL-ICs (n = 4) and
MCL-non-ICs (n = 4). Differences between MCL-ICs and MCL-non-ICs were significant (P < 0.05) for both genes
Mathur et al. Journal of Hematology & Oncology  (2015) 8:63 Page 5 of 12
Table 1 qRT-PCR analysis of Wnt ligands and FZD receptor expression in primary MCL cells compared to B-cells from healthy
donors
MCL-non-ICs MCL-ICs P value
Median 95 % CI Median 95 % CI
Wnt Ligands
Up-regulated in MCL-non-ICs and MCL-ICs
Wnt3a 17.555 0.12–56.05 34.52 2.49–91.86 0.0877
Wnt11 3.66 0.19–8.91 32.61 0.84–69.97 0.1588
Up-regulated in MCL-ICs
Wnt5a 1.78 0.76–21.93 10.5 3.56–17.87 0.3465
Wnt3 1.49 0.98–35.36 23.32 4.26–47.61 0.0500
Wnt8b 1.25 0.39–2.60 3.89 1.45–15.16 0.2308
Wnt4 1.76 0.21–6.13 3.41 0.54–5.65 0.2820
Wnt7a 1.21 0.75–5.32 2.09 0.60–6.76 0.2715
Wnt6 1.02 0.05–17.65 1.85 0.08–8.71 0.5133
Wnt5b 0.66 0.42–18.82 45.47 0.95–146.30 0.1956
Wnt1 0.45 0.15–12.25 9.26 4.18–15.20 0.1528
Wnt7b 0.28 0.25–2.24 4.15 2.13–7.85 0.0156
Wnt9b 0.39 0.15–1.47 2.44 1.08–8.79 0.1764
Wnt2b 0.28 0.16–8.18 1.39 0.05–9.60 0.0802
Wnt10a 0.67 0.24–14.80 0.96 0.03–4.41 0.5622
Up-regulated in MCL-non-ICs
Wnt9a 229.93 4.51–962.28 18.31 10.81–304.06 0.3201
Wnt16 11.99 1.32–32.97 4.61 3.23–9.86 0.3029
Wnt8a 6.97 0.24–18.73 1.01 0.15–2.32 0.1785
FZD Receptors
Up-regulated in MCL-non-ICs and MCL-ICs
Fz2 37.31 4.24–58.26 46.96 10.01–157.60 0.2909
Fz7 4.53 0.49–9.76 4.48 1.89–9.04 0.9536
Up-regulated in MCL-ICs
Fz4 1.15 0.07–2.52 122.7 1.93–1340 0.3002
Fz1 1.8 1.10–7.76 25.41 4.65–37.39 0.0390
Fz5 1.43 0.99–4.45 7.37 3.58–8.77 0.0100
Fz9 1.44 0.59–2.75 4.74 2.81–8.08 0.0379
Fz10 0.64 0.29–1.44 4.26 3.91–10.99 0.0738
Fz8 0.13 0.01–0.39 0.77 0.10–4.76 0.2907
Up-regulated in MCL-non-ICs
Fz6 5.02 4.47–5.59 1.34 0.66–1.85 0.0001
Fz3 0.3 0.12–7.04 0.26 0.24–1.22 0.4814
B-cells (median = 1) are used as reference. Median with 95 % confidence interval limits depicts the variations observed among patient samples. Differences
between MCL-ICs and MCL-non-ICs were considered as significant with P < 0.05.
MCL mantle cell lymphoma, ICs initiating cells
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showed that MCL-ICs have functional properties of can-
cer stem cells: high expression of ALDH, antioxidant en-
zymes, chemoresistance-associated genes, and stem cell-
associated transcription factors, while still retaining t
(11;14) (q13; q32) and overexpression of cyclin D1. Ouranalysis showed that MCL-ICs overexpress a subset of
Wnt ligands and FZD receptors and that Wnt signaling is
activated in MCL-ICs. Treatment of primary MCL cells
with Wnt inhibitors preferentially eliminated MCL-ICs,
which was not achieved with the current chemotherapy
agents vincristine, doxorubicin, or even with the recently
Fig. 4 Preferential elimination of MCL-ICs by inhibition of Wnt signaling. a Percentage of MCL-ICs evaluated by immunostaining and flow cytometry
(as shown in Fig. 1a) of primary MCL cells (n = 3) treated with vincristine (5 nM), doxorubicin (35 nM), or ibrutinib (10 μM), the Wnt inhibitors, CCT036477
(10 μM), iCRT14 (10 μM), or PKF118-310 (10 μM), for 48 h. *Differences between treated and control group were significant P < 0.05 (b–c) qRT-PCR analysis
of the expression of (b) Wnt target genes encoding PPARδ, Cyclin D1, Myc, TCF4, ID2, and (c) stem cell core transcription factors Nanog, Oct4, Myc, Sox2,
and Klf4 in MCL-ICs (n = 3) treated with 10 μM CCT036477 for 6 h. Gli2 is an off-target control. *P < 0.05
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(BTK) has been shown to be a negative regulator of Wnt
signaling [29]. Therefore, it is not surprising that ibrutinib
(a BTK inhibitor) probably resulted in inducing Wnt sig-
naling rather than inhibiting it and thereby could not
eliminate MCL-ICs. Our results suggest that the inability
of conventional chemotherapy to kill MCL-ICs can be
overcome by adding inhibitors of Wnt signaling.
A recent study showed that cobble stone area-forming
cells (CAFCs) that developed from MCL co-cultured with
human mesenchymal stem cells (hMSCs) are the morpho-
logic equivalent of MCL-ICs with the CD34-CD3-CD45
+CD19-CD133+ marker phenotype and manifested theirtumor-initiating capacity in NOD/SCID mice [26]. CAFCs
were also resistant to bortezomib, fludarabine, and doxo-
rubicin and expressed stem cell transcription factors Nanog
and Oct4 but not Sox2 [26]. The CD34-CD3-CD45+CD19-
MCL-ICs characterized in our study are identical to the
CAFCs; they were also CD133+ and exhibited the same
characteristics. However, our study has further extended
the characterization of MCL-IC, by identifying a hyper-
active Wnt signaling pathway, crucial for their maintenance
and survival.
Our results showed up-regulated expression of canonical
ligand Wnt3 [30] but not of the non-canonical ligands such
as Wnt4, Wnt5, and Wnt11 [31] in MCL-ICs compared to
Fig. 5 Schematic representation of Wnt pathway inhibition by small molecule inhibitors. Wnt pathway is turned off in the absence of Wnt ligand (left);
destruction complex involving APC, Axin-1, and GSK-3β interacts with and phosphorylates β-catenin leading to its degradation. Binding of Wnt ligands to
their cognate Frizzled (FZD) receptors and its co-receptors, low density lipoprotein receptor related proteins 5/6 (LRP5/6), activates the Wnt pathway (right)
leading to sequestration and degradation of Axin-1 and phosphorylation and degradation of GSK-3β. Degradation of destruction complex components
leads to accumulation of β-catenin and its subsequent translocation into the nucleus where it interacts with TCF4 to promote transcription of Wnt target
genes. IWR1 stabilizes Axin-1 and promotes formation of destruction complex and degradation of β-catenin (red arrows). IWP2 inhibits Porcupine-mediated
acylation and subsequent secretion of Wnt ligands. XAV939 inhibits Tankyrase-mediated degradation of Axin-1 and thus promotes formation of destruction
complex (red dashed arrow). CCT036477, iCRT14, and PKF118-310 target β-catenin-TCF4 transcription complex
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differentially higher staining of active unphosphorylated β-
catenin in MCL-ICs, which is required for canonical but
not for non-canonical Wnt pathway [32]. In addition, the
FZD6 receptor, which is associated with inhibition of ca-
nonical Wnt signaling pathway [33], was not differentially
expressed in MCL-ICs. These results clearly indicate the
presence of activated canonical Wnt signaling pathway in
MCL-ICs.
Other investigators have revealed that Wnt is an import-
ant pathway in primary MCL tissues and have implicated
this pathway in the pathogenesis of MCL [13]. Analysis of
unfractionated MCL shows only a threefold up-regulation
compared to B-cells in the previous study [13]. Our study
showed a 23-fold enhanced Wnt3 expression in MCL-ICs
compared to B-cells. These results clearly show the im-
portance of Wnt signaling in MCL-ICs.
MCL is believed to be driven by enhanced cyclin D1 ex-
pression due to t (11;14) (q13; q32) present in >90 % of
MCL [34, 35]. A minority of MCLs do not express cyclinD1 [36]. However, other isoforms of cyclin D are overex-
pressed in cyclin D1-negative MCLs, which suggests an
indispensable requirement for the expression of at least one
isoform of cyclin D in MCL [37]. Thus, it appears that
mechanisms other than t (11;14) (q13; q32) are responsible
for the overexpression of at least one other cyclin D in cyclin
D1-negative MCL. It is of interest that Wnt signaling could
potentially fulfill this role [38–40] as it was shown to up-
regulate cyclin D2 expression [41, 42]. Wnt3 was also noted
to be overexpressed in cyclin D1-negative MCL that also
lacked t (11;14) (q13; q32) [36]. Therefore, enhanced Wnt
signaling may be the underlying driver of overexpression of
cyclin D in all MCL regardless of t (11;14) status.
Overexpression of Wnt ligands and their cognate FZD
receptors in MCL-ICs points to the existence of an auto-
crine signaling loop. Immunostaining of β-catenin and
the elevated expression of Wnt target genes encoding
ID2 and TCF4 clearly confirmed higher Wnt activity in
MCL-ICs than in MCL-non-ICs. However, inhibitors of
Wnt signaling acting upstream of β-catenin degradation
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stream Wnt inhibitors targeting the β-catenin-TCF4 tran-
scription complex (CCT036477, iCRT14, and PKF118-310)
preferentially eliminated MCL-ICs over MCL-non-ICs.
These findings can be explained either by the very low ex-
pression of proteins involved in β-catenin degradation such
as GSK-3β and axin-1 (target of XAV939, IWR1-endo,
IWP2 compounds) observed in MCL-ICs or by a contribu-
tion of redundant and additional pathways to β-catenin ac-
tivation, such as autocrine fibroblast growth factor receptor
signaling [43, 44]. Further experiments will be required to
delineate the major contributors to β-catenin activation in
MCL-ICs.
We found elevated levels of FZD1 and its ligand Wnt3
in MCL-ICs as compared to MCL-non-ICs. Other re-
searchers have demonstrated that targeting FZD1 reverses
multidrug resistance in neuroblastomas and breast cancer
cells [45, 46]. Thus, Wnt3-FZD1 signaling may be one of
the reasons for chemoresistance in MCL [47, 48].
In summary, we have outlined an enhanced Wnt/β-ca-
tenin signaling in MCL-ICs and shown that inhibition of
the Wnt pathway effectively eliminates MCL-ICs, which
are implicated in MCL relapse. We have also demonstrated
that present therapy approaches for MCL, including re-
cently approved drug ibrutinib, do not address the killing of
MCL-ICs. Thus, we anticipate that current rates of MCL
relapse will not decrease substantially with current therap-
ies. A detailed examination of selectively enhanced signal-
ing in MCL-ICs may be a good starting point to expose
pathways important for MCL tumor stem cell survival. Pre-
senting clinical and MCL features at time of initial MCL
lymphoma presentation do not identify a priori, who are
the patients who will relapse from those will attain cures.
Perhaps, studying the MCL-IC and their response to target-
ing agents will be a key to identify patients who will relapse.
Our results clearly show that Wnt signaling inhibitors tar-
geting β-catenin-TCF4 interaction can eliminate MCL-ICs.
However, blocking the Wnt pathway exclusively in tumor
cells will be challenging, as Wnt signaling also has a role in
the self-renewal of non-malignant tissues such as intestinal
crypts, and bone growth plates [49, 50]. Nevertheless, our
results point to the important and actionable targets of
Wnt signaling in MCL pathogenesis and its potential use-
fulness as a target for therapy to eliminate MCL-ICs and re-
duce the risk of MCL relapse.
Conclusions
Our results clearly demonstrate the differential activation
of Wnt pathway in MCL-ICs. Not all steps in the Wnt sig-
naling pathway are amenable to effective blocking in
MCL. We show that blocking of Wnt signaling at the β-
catenin-TCF4 transcription complex effectively blocks sig-
naling in MCL-IC and preferentially kills the MCL-IC
cells, which harbor chemoresistance. This study resultsshows identification of effective agents in MCL-IC that
would not had been possible by studying whole MCL cells.
Since inhibition of Wnt pathway resulted in preferential
elimination of MCL-ICs, we conclude that Wnt pathway
should be targeted to eliminate MCL-ICs and reduce the
risk of relapsed MCL.
Methods
Patients and agents
Cells and clinical information from MCL patients described
in this manuscript (Additional file 4: Table S2) were col-
lected and published with the written informed consent of
each patient under The University of Texas MD Anderson
Cancer Center IRB-approved clinical protocol LAB08-0190
for use of human tissues.
The following agents were tested: Wnt inhibitors
XAV939 (Selleck Chemicals, Houston, TX), iCRT14 (R&D
Systems, Minneapolis, MN), CCT036477, PKF118-310
(Sigma-Aldrich, St. Louis, MO), IWP2, IWR1-endo, and
IWR1-exo (Santa Cruz Biotechnologies, Santa Cruz, CA);
Hedgehog inhibitors GANT61 (R&D Systems, Minneap-
olis, MN), LDE225 and Cyclopamine (both from Selleck
Chemicals, Houston, TX); Notch inhibitor RO4929097
(Selleck Chemicals, Houston, TX).
Isolation of normal B-cells
Peripheral blood B-cells were isolated from healthy donors’
blood obtained from the Gulf Coast Blood Center (Houston,
TX) by using CD19-positive magnetic beads and were
released with the competitive CD19 DETACHaBEAD ac-
cording to the manufacturer’s instructions (Invitrogen-Life
Technologies, San Diego, CA). All procedures were per-
formed under The University of Texas MD Anderson Can-
cer Center IRB-approved clinical protocol LAB08-0190.
Isolation of MCL cells and MCL-ICs
MCL tumor cell-enriched buffy coats were isolated from
apheresis or leukemic phase blood of MCL patients by
Histopaque-1077 (Sigma-Aldrich, St. Louis, MO) gradi-
ent centrifugation. Obtained cells were then stained with
antibodies against CD34-APC (Cat No. 555824), CD3-
APC-Cy7 (Cat No. 557832), CD45-FITC (Cat No.
555482), CD19-PE (Cat No. 555413), and Sytox blue for
selection of live cells (all from BD Bioscience, San Jose,
CA). Subpopulations of MCL-ICs (CD34-CD3-CD45
+CD19-) and MCL-non-ICs (CD34-CD3-CD45+CD19+)
were isolated using a fluorescence-activated cell sorter
(Influx, BD Bioscience, San Jose, CA) according to a pre-
viously described protocol [25]. Subpopulations of sorted
cells were analyzed for purity by immunostaining with
markers for plasma cells (CD27, CD38) and natural
killer cells (CD56, CD16) using the antibodies CD27-
PerCP-Cy5.5 (Cat No. 560612), CD38-PE-Cy7 (Cat No.
560677), CD56-PE-Cy7 (Cat No. 557747), and CD16-
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San Jose, CA), respectively.
ALDH activity assay
ALDH activity in cells was determined by using an ALDE-
FLUOR kit according to the manufacturer’s protocol
(STEMCELL Technologies, Vancouver, Canada). Briefly, 1
× 106 cells were resuspended in a 1 ml assay buffer with 5
μl of ALDEFLOUR reagent. DEAB was used as inhibitor
of ALDH activity. A 500-μl aliquot of the reagent mixed
cells was transferred to an Eppendorf tube containing 5 μl
of DEAB as a control. Samples were incubated at 37 °C
for 45 min. Green fluorescence intensity was measured
with a BD Fortessa flow cytometer (Becton Dickinson, San
Jose, CA) and evaluated with FlowJo software (Tree Star,
Ashland, OR).
Fluorescent in situ hybridization
Isolated MCL-ICs, MCL-non-ICs, and B-cells from healthy
donors were affixed on slides (Statlab, McKinney, TX) using
cytospin. Slides were fixed using SAFETEX cytology spray
(Andwin Scientific, Woodland Hills, CA) and hybridized
using Vysis IgH/CCND1 probe kit (Abbot molecular, Ab-
bott park, IL) to confirm the presence of t (11;14) (q13;
q32). Staining was assessed using a Bioview Duet imaging
system (Bioview, Nes Ziona, Israel) equipped with an
Olympus BX61 microscope (Olympus America, Center
Valley, PA).
Quantitative real-time polymerase chain reaction
(qRT-PCR)
Total RNA was extracted from cells using RNAqueous kit
according to the manufacturer’s protocol (Ambion-Life
Technologies, Austin, TX). First-strand cDNA was synthe-
sized using a Superscript III reverse transcriptase kit ac-
cording to the manufacturer’s protocol (Invitrogen-Life
Technologies, San Diego, CA). Samples were analyzed on
96-well microtiter plates using the StepOnePlus real-time
PCR System (Applied Biosystems, Grand Island, NY). qRT-
PCR was performed using SYBR green dye and primers
specific for selected human genes (Additional file 5: Table
S1) as described earlier [51, 52]. PCR was performed with
40 cycles of 95 °C for 15 s and 60 °C for 1 min. Step-One
software version 2.1 was used to analyze the qRT-PCR data.
Immunostaining
Cells were immobilized on glass slides by using cytospin
prior to fixation in methanol for 1 h at −20 °C. Cells
were permeabilized using 0.5 % Triton-×100 in PBS for
20 min at room temperature prior to staining with non-
phosphorylated (active) anti-β-catenin antibody (1 μg,
Cat No. 8814S, Cell Signaling, Danvers, MA) and
AlexaFluor-488-conjugated secondary antibody (1:500,
Cat No. A11008, Life Technologies, San Diego, CA).Slides were washed with 0.1 % Tween 20 and mounted
with ProLong Gold antifade reagent containing nuclear
stain 4′,6 diamidino-2-phenylindole dihydrochloride
(DAPI) (Invitrogen-Life Technologies, San Diego, CA).
Images were acquired at 60× using A1R confocal laser
microscope system (Nikon Instruments, Melville, NY).
Growth and treatment of MCL cells
Primary MCL cells were seeded onto a layer of human
bone marrow mesenchymal stromal cells (hMSCs) at a
MCL to a stromal cell ratio of 10:1 and grown in hMSC
medium supplemented with mesenchymal cell growth fac-
tors and glutamine (Lonza, Allendale, NJ) at 37 °C in 5 %
CO2 as described previously [53]. MCL cells were har-
vested, resuspended in 50 % fresh and 50 % conditioned
medium from hMSC cultures, and incubated with the in-
dicated agents for 6–48 h. Cells were either stained with
propidium iodide for cell cycle analysis as described earlier
[54] or had RNA isolated for further analysis. The percent-
age of MCL-ICs was determined using procedures de-
scribed in the “Isolation of MCL cells and MCL-ICs”
section above.
Statistical analysis
Experimental data are reported as means or medians with
standard deviation or error of mean, unless otherwise in-
dicated. Differences between groups were calculated using
the two-tailed Student’s t test (GraphPad Prism, GraphPad
Software, Inc, La Jolla, CA). P < 0.05 was considered sta-
tistically significant.
Additional files
Additional file 1: Figure S1. Wnt signaling pathway is active in MCL-ICs.
Detection β-catenin expression and localization by immunofluorescence
and confocal microscopy in (a) B-cells from healthy donors and in (b) freshly
isolated MCL-ICs, and MCL-non-ICs.
Additional file 2: Figure S2. Inhibition of Wnt signaling induce
apoptosis of primary MCL cells. (a) Percentage apoptosis, sub-G1 analysis
of primary MCL cells (n = 3) treated with vincristine (5 nM), doxorubicin
(35 nM), or ibrutinib (10 μM), the Wnt inhibitors, CCT036477 (10 μM),
iCRT14 (10 μM), or PKF118-310 (10 μM), for 48 h. *Differences between
treated and control group were significant P < 0.05.
Additional file 3: Figure S3. Hedgehog and Notch signaling pathways
in MCL-ICs. Expression of mRNA encoding (a) Hedgehog signaling
pathway transcription factors Gli1, Gli2, Gli3 and (b) Notch signaling
target genes Hes1, Hes5 and Hey1 in freshly isolated MCL-ICs, and
MCL-non-ICs relative to B-cells from healthy donors. Horizontal lines
represent median for each group. Differences between MCL-ICs and
MCL-non-ICs were significant (P < 0.05) for Gli3, and Hey1. (c) Percentage
of MCL-ICs evaluated by immunostaining and flow cytometry (as shown
in Fig. 1a) of primary MCL cells (n = 3) treated with Hedgehog inhibitors
LDE225 (5 μM), Cyclopamine (5 μM), GANT61 (5 μM) and Notch inhibitor
RO4929097 (5 μM) for 48 h. *Differences between treated and control
group were significant P < 0.05. Overexpression of Gli3, a repressor of
hedgehog pathway [55, 56] in MCL-ICs and inability of hedgehog and
notch signaling pathway inhibitors to decrease percentage of MCL-ICs,
suggest that these pathways may not be effective targets for reducing
the percentage of MCL-ICs.
Mathur et al. Journal of Hematology & Oncology  (2015) 8:63 Page 11 of 12Additional file 4: Table S2. Clinical information of patients submitting
primary MCL tissue for analysis.
Additional file 5: Table S1. List of primers.
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